{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-070387","form_type":"8-K","ticker":"HSCS","cik":"0001468492","company_name":"HeartSciences Inc.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.157493+00:00","generated_at":"2026-06-07T12:43:41.702283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HeartSciences Q2 cash $100K, equity deficit; raises $9.3M post-quarter, Mount Sinai deal expands AI-ECG platform","bullets":["Q2 FY2024: no significant revenue; cash ~$100K; shareholders' equity deficit ~$1.6M as of Oct 31, 2023.","After quarter close: raised $9.3M net from stock sales, converted $1.1M debt to equity, closed license agreements with Mount Sinai (became material shareholder).","FDA confirmed 510(k) pathway for MyoVista wav ECG device; target clearance in CY2024, expected to save millions and years for future algorithms.","Expanded IP to 42 patents; new distributor agreements in India and Nordic countries; selected by CardiACT for Irish police officer screening.","CEO states shareholders' equity now >$5M; may seek second 180-day Nasdaq bid price grace period if needed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-070387","json":"https://secwatch.observer/filing/0000950170-23-070387.json","markdown":"https://secwatch.observer/filing/0000950170-23-070387.md","text":"https://secwatch.observer/filing/0000950170-23-070387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023070387/0000950170-23-070387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023070387/hscs-20231214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:43:41.702283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"696f388cf5f9e95eaf54483adeb753d25d671759","claim":"HeartSciences Inc. reported the second quarter fiscal 2024 ended October 31, 2023 results: revenue There were no significant revenues.","evidence_excerpt":"Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (\"HeartSciences\" or the \"Company\"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023070387/0000950170-23-070387-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter fiscal 2024 ended October 31, 2023"},{"label":"Revenue","value":"There were no significant revenues"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}